查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433347

2023-2030 年全球多重檢測市場

Global Multiplex Assays Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

預計在預測期內（2023-2030 年），全球多重檢測市場將以 14.8% 的CAGR成長。市場的成長歸因於免疫療法的不斷進步。免疫療法，特別是嵌合抗原受體 (CAR) T 細胞療法在癌症治療中的使用增加，增加了對 CAR-T 細胞精確測量和監測的需求。多重數位 PCR 檢測可透過提供確定治療成功所需的準確、全面的分析來滿足需求。例如，2023 年6 月，BioPharma Services, Inc. 推出了新的多重數位PCR 檢測，用於對多種CAR-T 細胞進行全面定量，這是一種癌症免疫療法，涉及對T 細胞進行基因改造以識別和消滅某些癌症。該分析基於 Qiagen QIAcuity 數位 PCR 方法，該方法透過其獨特的奈米板方法提供強大而簡單的數位 PCR 體驗。

區隔市場前景

全球多重檢測市場依類型、技術和最終用戶進行區隔。根據類型，市場區隔為蛋白質多重檢測、基於核酸的多重檢測和基於細胞的多重檢測。根據技術，市場區隔為多重即時 PCR、Luminex 微珠技術、流式細胞儀等。此外，根據最終用戶，市場區隔為製藥和生物製藥公司、CRO、研究和學術機構等。在這些類型中，基於核酸的多重檢測子類別預計將佔據很大一部分市場佔有率。這歸因於基於核酸的多重測定的使用和基於核酸的多重測定的研究的增加。

多重即時 PCR 區隔市場預計將在全球多重檢測市場中佔據相當大的佔有率

在這些技術中，多重即時 PCR 子領域預計將在全球多重檢測市場中佔據相當大的佔有率。部門成長歸因於測試效率的提升。多重檢測透過在單一回應中檢測多個目標來簡化測試。在一次反應中識別兩個 N 基因標靶序列的能力減少了測試時間，提高了通量，並提高了診斷實驗室效率。例如，2020 年 5 月，Gold Standard Diagnostics 推出了針對 SARS-CoV-2 的多重即時 PCR 檢測。 GSD NovaPrime SARS-CoV-2 (COVID-19) 是一種即時 PCR 檢測，旨在檢測 SARS-CoV-2。這是一種多重測試，可在一次反應中檢測 N 基因的兩個目標序列，並在 2 小時內提供結果。試劑包括萃取/抑制對照和陽性對照。

區域展望

全球多重檢測市場根據地理位置進一步區隔，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本） 、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於患有慢性和傳染病的人數不斷增加，以及對多重檢測產品和服務的使用意識不斷提高，預計北美將在全球市場中佔據顯著佔有率。

北美地區預計全球多重檢測市場將以顯著的CAGR成長

在所有地區中，北美地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於大流行的防範和監測。主要促進因素是迫切需要精確、高效的血清學檢測，以檢測先前的感染情況並追蹤 COVID-19 大流行期間的人群暴露率。具有高特異性和敏感性的多重檢測（例如這种血清學檢測）對於人群層面的監測至關重要。據美國國立衛生研究院 (NIH.gov) 稱，2022 年 1 月，使用兩組康復者的血清樣本開發並驗證了一种血清學 COVID-19 多重檢測方法；以及那些尚未被感染的人。在測試了多種潛在抗原後，選擇 SARS-CoV-2 核衣殼蛋白 (NP) 和刺突蛋白的受體結合域 (RBD) 進行人類 COVID-19 多重檢測。合成的 RBD 蛋白與哺乳動物表現的 RBD 蛋白的比較顯示了哺乳動物表現的優勢。 NP 和 RBD 特異性 IgG 和 IgA 的檢測在區分患者和對照組方面具有出色的性能（AUC > 0.90），並且 IgG 檢測具有更寬的動態範圍。該測定用於評估居住在紐約州伊薩卡低發病率社區的人們的 SARS-CoV-2 血清陽性率。 2020 年採樣的 332 名健康志願者中，1.2-5.7% 的 NP 或 RBD 檢測呈陽性，高於該縣報告的 0.16% 的發病率。此測定可用於監測社區暴露率以及感染或疫苗接種後免疫反應的持續時間。

市場參與者展望

服務全球多重檢測市場的主要公司包括 Bio-Rad Laboratories, Inc.、Merck Group、PerkinElmer US LLC、Quansys Biosciences Inc.、Thermo Fisher Scientific Inc. 等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2023年7月，EDP Biotech與New Day Diagnostics合併，成立一家垂直整合的診斷公司，以推進診斷測試的開發和商業化。 EDP​​ 提供 ColoPlex 體外診斷測定，有助於早期檢測癌前息肉和大腸直腸癌。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個區隔市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 全球多重檢測市場的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵區隔市場來分析業務策略。
  • 市場進入和市場擴張策略分析。透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 依區隔
    • 依地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Abcam plc
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Agilent Technologies
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • BioMerieux SA
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場區隔

  • 依類型分類的全球多重分析市場
    • 蛋白質多重檢測
    • 基於核酸的多重檢測
    • 基於細胞的多重檢測
  • 依技術分類的全球多重檢測市場
    • 多重即時 PCR
    • Luminex 珠技術
    • 流式細胞儀
    • 其他（次世代定序 (NGS) 和微陣列技術）
  • 依最終用戶分類的全球多重分析市場
    • 製藥和生物製藥公司
    • 合約研究組織 (CRO)
    • 研究和學術機構
    • 其他（生物技術和製藥公司以及臨床診斷實驗室）

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corp.
  • BioTools Inc.
  • CareDx, Inc.
  • Diasorin S.p.A.
  • Hologic, Inc.
  • Illumina, Inc.
  • Merck Group
  • Meso Scale Diagnostics, LLC
  • PerkinElmer U.S. LLC
  • Promega Corp.
  • QIAGEN GmbH
  • Quansys Biosciences Inc.
  • Randox Laboratories
  • Seegene, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: OMR2027948

Global Multiplex assays Market Size, Share & Trends Analysis Report by Type (Protein Multiplex Assays, Nucleic Acid-Based Multiplex Assays, and Cell-based Multiplex Assays), by Technology (Multiplex Real-Time PCR, Luminex Bead Technology, Flow Cytometry, and Others), and by End-User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations (CROs), Research and Academic Institutions, Others), Forecast Period (2023-2030)

The global multiplex assays market is anticipated to grow at a CAGR of 14.8% during the forecast period (2023-2030). The market's growth is attributed to the increasing advancements in immunotherapy. The increased use of immunotherapy, particularly chimeric antigen receptor (CAR) T cell therapy, for cancer treatment increases the need for accurate measurement and monitoring of CAR-T cells. Multiplex digital PCR assays satisfy the demand by delivering accurate, comprehensive analysis necessary for determining therapy success. For instance, in June 2023, BioPharma Services, Inc., launched new multiplex digital PCR assays for comprehensive quantification of multiple CAR-T cells, a type of cancer immunotherapy that involves genetically modifying T-cells to recognize and destroy certain cancers. The analysis is based on the Qiagen QIAcuity digital PCR methodology, that offers a powerful yet simple digital PCR experience with its unique nanoplate methodology.

Segmental Outlook

The global multiplex assays market is segmented on the type, technology, and end-user. Based on the type, the market is sub-segmented into protein multiplex assays, nucleic acid-based multiplex assays, and cell-based multiplex assays. Based on the technology, the market is sub-segmented into multiplex real-time PCR, Luminex bead technology, flow cytometry, and others. Further, based on the end-user, the market is sub-segmented into pharmaceutical and biopharmaceutical companies, CROs, research and academic institutions, and others. Among the type, the nucleic acid-based multiplex assays subcategory is expected to capture a significant portion of the market share. This is attributed to the increase in the usage of nucleic acid-based multiplex assays and research on nucleic acid-based multiplex assays.

The Multiplex Real-Time PCR Sub-Segment is Anticipated to Hold a Considerable Share of the global Multiplex assays Market

Among the technology, the multiplex real-time PCR sub-segment is expected to hold a considerable share of the global multiplex assays market. The segmental growth is attributed to the enhanced testing efficiency. Multiplex assays simplify testing by detecting several targets in a single response. The capacity to recognize two N-gene target sequences in a single reaction decreases testing time, boosts throughput, and enhances diagnostic laboratory efficiency. For instance, in May 2020, Gold Standard Diagnostics Launched Multiplex Real-Time PCR Assay for SARS-CoV-2. GSD NovaPrime SARS-CoV-2 (COVID-19) is a real-time PCR test designed to detect SARS-CoV-2. It is a multiplex test which detects two target sequences of the N-gene in one reaction, providing results in 2 hours. The reagents include an extraction/ inhibition control and a positive control.

Regional Outlook

The global multiplex assays market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market around the globe, owing to the increasing number of individuals suffering from chronic and infectious diseases, in addition to increased awareness of the usage of multiplex assay products and services.

The North America Region is Expected to Grow at a Significant CAGR in the global Multiplex Assays Market

Among all regions, the North America region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the pandemic preparedness and surveillance. A primary driving element is the urgent need for precise and efficient serological assays to detect prior infections and track population exposure rates during the COVID-19 pandemic. Multiplex assays with high specificity and sensitivity, such as this serological assay, are essential in population-level surveillance. According to the National Institute of Health (NIH.gov), in January 2022, a serological COVID-19 multiplex assay was developed and validated using serum samples from 2 groups of recovered people; and those who had not yet been infected. After testing multiple potential antigens, the SARS-CoV-2 nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were selected for the human COVID-19 multiplex assay. A comparison of synthesized and mammalian expressed RBD proteins showed the advantages of mammalian expression. Detection of NP and RBD specific IgG and IgA had excellent performance (AUC > 0.90) for distinguishing patients from controls, with the IgG assay having a wider dynamic range. This assay was used to evaluate seroprevalence to SARS-CoV-2 in people living in a low-incidence community in Ithaca, NY. Of the 332 healthy volunteers sampled 2020, 1.2-5.7% tested positive for either NP or RBD, which was higher than the county's reported incidence rate of 0.16%. This assay can be used to monitor community exposure rates and the duration of immune response following infection or vaccination.

Market Players Outlook

The major companies serving the global multiplex assays market include Bio-Rad Laboratories, Inc., Merck Group, PerkinElmer U.S. LLC, Quansys Biosciences Inc., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2023, EDP Biotech merged with New Day Diagnostics to form a vertically integrated diagnostic company to advance the development and commercialization of diagnostic tests. EDP offers the ColoPlex in vitro diagnostic assay, that assists in the early detection of pre-cancerous cancer polyps and colorectal cancer.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global multiplex assays market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abcam plc
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Agilent Technologies
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. BioMerieux SA
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Multiplex Assays Market by Type
    • 4.1.1. Protein Multiplex Assays
    • 4.1.2. Nucleic Acid-Based Multiplex Assays
    • 4.1.3. Cell-based Multiplex Assays
  • 4.2. Global Multiplex Assays Market by Technology
    • 4.2.1. Multiplex Real-Time PCR
    • 4.2.2. Luminex Bead Technology
    • 4.2.3. Flow Cytometry
    • 4.2.4. Others (Next-Generation Sequencing (NGS), and Microarray Technology)
  • 4.3. Global Multiplex Assays Market by End-User
    • 4.3.1. Pharmaceutical and Biopharmaceutical Companies
    • 4.3.2. Contract Research Organizations (CROs)
    • 4.3.3. Research and Academic Institutions
    • 4.3.4. Others (Biotechnology and Pharmaceutical Companies, and Clinical Diagnostics Labs)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bio-Rad Laboratories, Inc.
  • 6.2. Bio-Techne Corp.
  • 6.3. BioTools Inc.
  • 6.4. CareDx, Inc.
  • 6.5. Diasorin S.p.A.
  • 6.6. Hologic, Inc.
  • 6.7. Illumina, Inc.
  • 6.8. Merck Group
  • 6.9. Meso Scale Diagnostics, LLC
  • 6.10. PerkinElmer U.S. LLC
  • 6.11. Promega Corp.
  • 6.12. QIAGEN GmbH
  • 6.13. Quansys Biosciences Inc.
  • 6.14. Randox Laboratories
  • 6.15. Seegene, Inc.
  • 6.16. Thermo Fisher Scientific Inc.

LIST OF TABLES

  • 1. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL PROTEIN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL NUCLEIC ACID-BASED MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CELL-BASED MULTIPLEX ASSAYS RESEARCH MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 6. GLOBAL MULTIPLEX ASSAYS BY MULTIPLEX REAL-TIME PCR MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL MULTIPLEX ASSAYS BY LUMINEX BEAD TECHNOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL MULTIPLEX ASSAYS BY FLOW CYTOMETRY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL MULTIPLEX ASSAYS BY OTHER TECHNOLOGIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 11. GLOBAL MULTIPLEX ASSAYS FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL MULTIPLEX ASSAYS FOR CONTRACT RESEARCH ORGANIZATIONS (CRO) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL MULTIPLEX ASSAYS FOR RESEARCH AND ACADEMIC INSTITUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL MULTIPLEX ASSAYS FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 20. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 23. EUROPEAN MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD MULTIPLEX ASSAYS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL PROTEIN MULTIPLEX ASSAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL NUCLEIC ACID-BASED MULTIPLEX ASSAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CELL-BASED MULTIPLEX ASSAYS RESEARCH MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 6. GLOBAL MULTIPLEX ASSAYS BY MULTIPLEX REAL-TIME PCR MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL MULTIPLEX ASSAYS BY LUMINEX BEAD TECHNOLOGY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL MULTIPLEX ASSAYS BY FLOW CYTOMETRY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL MULTIPLEX ASSAYS BY OTHER TECHNOLOGIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 11. GLOBAL MULTIPLEX ASSAYS FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL MULTIPLEX ASSAYS FOR CONTRACT RESEARCH ORGANIZATIONS (CRO) MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL MULTIPLEX ASSAYS FOR RESEARCH AND ACADEMIC INSTITUTIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL MULTIPLEX ASSAYS FOR OTHER END-USERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL MULTIPLEX ASSAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD MULTIPLEX ASSAYS MARKET SIZE, 2022-2030 ($ MILLION)